Issues related to patient access to treatments Issues related to rare diseases such as Duchenne Muscular Dystrophy Issues related to newborn screening for rare diseases
2025 · 3rd Quarter (July 1 - Sep 30)
SAREPTA THERAPEUTICS, INC.
Filed by SAREPTA THERAPEUTICS, INC..
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 15, 2025
- Income
- Not reported
- Expenses
- $430,000.00
- Registrant
- SAREPTA THERAPEUTICS, INC.
- Filing UUID
- afebabf8-beff-41a3-a2ea-c191bfc5223c
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Issues related to the Inflation Reduction Act's prescription drug provisions
Issues related to scientific innovation in healthcare such as gene therapies Issues related to artificial intelligence and data governance
Tax issues related to research and development
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.